Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Investors bought 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the typical volume of 53 put options.

Analyst Upgrades and Downgrades

MRVI has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.86.

Maravai LifeSciences Stock Down 3.7%

Shares of NASDAQ:MRVI traded down $0.14 during trading on Thursday, reaching $3.68. 298,294 shares of the company traded hands, compared to its average volume of 1,128,547. The firm has a fifty day simple moving average of $3.46 and a 200 day simple moving average of $3.23. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $4.11. The firm has a market cap of $941.01 million, a P/E ratio of -4.09 and a beta of 0.38.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $49.87 million during the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%. Analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Insider Activity at Maravai LifeSciences

In related news, Director Gregory T. Lucier acquired 48,528 shares of Maravai LifeSciences stock in a transaction dated Monday, December 8th. The stock was acquired at an average cost of $3.67 per share, with a total value of $178,097.76. Following the purchase, the director directly owned 155,123 shares in the company, valued at $569,301.41. The trade was a 45.53% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.11% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Sprott Inc. bought a new stake in Maravai LifeSciences in the third quarter worth approximately $29,000. Quantessence Capital LLC acquired a new position in Maravai LifeSciences during the third quarter worth $31,000. Abel Hall LLC bought a new stake in shares of Maravai LifeSciences during the 3rd quarter worth about $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences during the third quarter worth approximately $33,000. Finally, Virtu Financial LLC bought a new stake in shares of Maravai LifeSciences during the 4th quarter worth $34,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.